ライフサイエンスコーパス: immunogenicity

1 hibited distinct patterns of IgE binding and immunogenicity.

2 subtrial was embedded to evaluate safety and immunogenicity.

3 ons, was attenuating and resulted in reduced immunogenicity.

4 r improving in silico predictions of peptide immunogenicity.

5 igens, are typically ineffective due to poor immunogenicity.

6 h are generally considered as having limited immunogenicity.

7 the antibodies, their limited half-life, and immunogenicity.

8 of mAbs against some glycan targets with low immunogenicity.

9 or attenuation in vivo, resulting in reduced immunogenicity.

10 ly, the number of mutations determines tumor immunogenicity.

11 DCs had a compromised maturation ability and immunogenicity.

12 the need to identify methods to limit FVIII immunogenicity.

13 ens while maintaining full functionality and immunogenicity.

14 tration of different OPV formulations on RV1 immunogenicity.

15 ses induced in two small-animal models of MV immunogenicity.

16 n serve as Ag-delivery vehicles that enhance immunogenicity.

17 ooled with the non-deployed group to compare immunogenicity.

18 eir relationship to protein interactions and immunogenicity.

19 s that may be manipulated to enhance vaccine immunogenicity.

20 iotics would improve oral poliovirus vaccine immunogenicity.

21 regulation in tumor cells and enhanced their immunogenicity.

22 (NII) to evaluate an epitope's neutralizing immunogenicity.

23 ivalent, or trivalent OPV seems to lower RV1 immunogenicity.

24 for the immunoproteasome in improving tumor immunogenicity.

25 cacious but were ultimately limited by their immunogenicity.

26 sting that genetics might play a role in PEG immunogenicity.

27 have been evaluating means to increase RSV F immunogenicity.

28 were safety, response, pharmacokinetics, and immunogenicity.

29 be safely treated with rFVIII, as relates to immunogenicity.

30 therefore can efficiently improve vaccines' immunogenicity.

31 jugation of IT to polyethylene glycol limits immunogenicity.

32 increased attenuation in vivo but increased immunogenicity.

33 istinct clades have been proposed to improve immunogenicity.

34 take, prolonged circulation time and reduced immunogenicity.

35 hance packaging into the vector particle and immunogenicity.

36 The secondary endpoint in both trials was immunogenicity 4 weeks after last vaccination.

37 odies (MAbs) and the DPP4 receptor, and high immunogenicity, able to elicit S-specific antibodies.

38 pment that can be tested in vitro to confirm immunogenicity, absence of homology and global populatio

39 A second TDV dose induced enhanced immunogenicity against DENV-3 and DENV-4 in children who

40 s assessed the safety of the vaccine and its immunogenicity against diverse strains of group B mening

41 e no significant differences in baseline RV1 immunogenicity among the 409 infants included in the fin

42 ived at least one trial vaccination) and the immunogenicity analyses were based on the per-protocol p

43 Low tumor immunogenicity and a strong immunosuppressive tumor micr

44 ation of vancomycin greatly dampened both CT immunogenicity and adjuvanticity, and the differential C

45 Secondary outcomes included immunogenicity and antibody functionality, and the incid

46 ole of the Hippo pathway in modulating tumor immunogenicity and demonstrate a proof of concept for ta

47 ese properties, combined with their inherent immunogenicity and demonstrated efficacy against a poorl

48 e biomimetic particulates showed a promising immunogenicity and efficacy profile that may be improved

49 us macaques, commonly used to assess vaccine immunogenicity and efficacy.

50 kable efficacy targeting tumor antigens, but immunogenicity and endogenous biotin blocking may limit

51 ific PRIT, combined with its reduced risk of immunogenicity and endogenous biotin interference, make

52 ity, low or negligible toxicity, often a low immunogenicity and finally an ease of chemical modificat

53 ased apoptosis, cell-cycle arrest, and tumor immunogenicity and generated immunogenic cell death in h

54 Here, we review key aspects of HIV-1 Env immunogenicity and immunogen re-design, based on experim

55 ed CD4(+) and CD8(+) T cell infiltration and immunogenicity and induced tumor protection suggesting t

56 ith stage III or IV melanoma and demonstrate immunogenicity and intriguing clinical safety and effica

57 optotic cancer cell death, with focus on its immunogenicity and its role in the activation of anti-tu

58 ritical barriers on account of its potential immunogenicity and limited payload capacity.

59 omposition correlates significantly with RVV immunogenicity and may contribute to the diminished RVV

60 A-mediated antigen presentation affect tumor immunogenicity and may play a role in shaping cancer cel

61 ble and biodegradable, together with reduced immunogenicity and natural capabilities to target cancer

62 A single dose of H3N8 LACIV showed immunogenicity and protection against a homologous chall

63 Immunogenicity and protection efficacy were better than

64 or variant ZIKV structural genes and tested immunogenicity and protection in mice.

65 Here we evaluated the immunogenicity and protective capacity of the recombinan

66 ctor packaging significantly improved vector immunogenicity and protective efficacy against RSV.

67 ctors expressing RSV glycoproteins for their immunogenicity and protective efficacy in cotton rats an

68 essed the potential influences of PEM on the immunogenicity and protective efficacy of avian influenz

69 To this end, we demonstrate the immunogenicity and protective efficacy of FILORAB1, a re

70 icate that CDK4/6 inhibitors increase tumour immunogenicity and provide a rationale for new combinati

71 ttenuated in vivo, while they retained their immunogenicity and provided protection against a lethal

72 Safety was evaluated over 180 days; immunogenicity and RSV infection rates were evaluated ov

73 All immunogenicity and safety analyses were done on the full

74 ent-inactivated influenza vaccine (IIV4) for immunogenicity and safety in adults 18-49 years of age.

75 We assessed the immunogenicity and safety of a novel monovalent high-dos

76 The immunogenicity and safety of an adjuvanted herpes zoster

77 dy provided preliminary evidence of the good immunogenicity and safety of hepatitis B vaccination amo

78 Immunogenicity and safety of inactivated zoster vaccine

79 ccine development involves tradeoffs between immunogenicity and safety.

80 optimum dose in terms of clinical efficacy, immunogenicity and safety.

81 ovides a structural explanation of E1 and E2 immunogenicity and sheds light on the molecular processe

82 bilized form of RSV F demonstrated promising immunogenicity and should be further developed as an int

83 The data suggested a link between immunogenicity and specificity for nucleosomes.

84 The increased immunogenicity and speed of evolution in minor-group lin

85 Safety and immunogenicity and the effect of baseline vector immunit

86 In addition, cell transplantation carries immunogenicity and/or tumourigenicity risks.

87 Safety, efficacy, pharmacokinetics, immunogenicity, and accelerated daratumumab infusions we

88 We describe safety, immunogenicity, and acceptability of the first-in-man st

89 VIII plays a crucial role in FVIII function, immunogenicity, and clearance, with VWF essentially serv

90 immune recognition associated with stem cell immunogenicity, and discuss the relevance of reprogrammi

91 gh binding affinity, good stability, lack of immunogenicity, and easy synthesis, aptamer GR-3 against

92 re-fusion antigen levels, thermal stability, immunogenicity, and efficacy despite heavy attenuation i

93 We aimed to assess the safety, immunogenicity, and efficacy of maternal immunisation wi

94 n green monkey models for their replication, immunogenicity, and efficacy of protection against RSV c

95 We evaluated the toxicity, immunogenicity, and efficacy of the ICs targeted with 7B

96 inical trial in 2011 and 2012 on the safety, immunogenicity, and efficacy of trivalent inactivated in

97 unodominant domain (PID) because of its high immunogenicity, and it is essential for gp41-mediated HI

98 BsAbs, including their assembly, stability, immunogenicity, and pharmacodynamics.

99 Here we describe the construction, immunogenicity, and preliminary information on the prote

100 ook this randomised, double-blind, efficacy, immunogenicity, and safety study of the 9vHPV vaccine st

101 tained good functionality, antigenicity, and immunogenicity, and they induced strong cross-neutralizi

102 Differences in tumor immunogenicity appear to underlie their relative importa

103 Innovative ways to enhance their immunogenicity are being tested, but rational sequence m

104 Having identified immunogenicity as a major concern, we show that conjugat

105 We have assessed whether HLA immunogenicity as defined by differences in donor-recipi

106 n unwanted side effects (e.g., hemorrhage or immunogenicity) as well as enhancements of efficacy and

107 e ITs with polyethylene glycol minimized the immunogenicity, as has been demonstrated with other prot

108 cuss potential implications of EMT for tumor immunogenicity, as well as current immunotherapies and f

109 II collagen scaffolds, which avoid potential immunogenicity associated with fibrillar collagens, were

110 The apparently low immunogenicity associated with H7 viruses and vaccines m

111 ears since RV144 vaccination, for safety and immunogenicity, at weeks 0 and 24.

112 17 healthy donors and define a hierarchy of immunogenicity based on the frequency of responding dono

113 Substantial differences in safety or immunogenicity between modes of DNA delivery were not ob

114 generation immunogen, DEKnull-2, provides an immunogenicity breakthrough to conserved protective epit

115 T modification did not increase packaging or immunogenicity but rather reduced the stability of GP ex

116 different cancer cells, and attenuates their immunogenicity by degrading DNA that accumulates in the

117 V3 non-NAb epitopes and thereby reduce their immunogenicity by introducing N-glycans within the V3 re

118 V3 immunogenicity can be diminished, but not abolished, by

119 Immunogenicity can have devastating consequences on the

120 ervational study nested within a comparative immunogenicity clinical trial of adjuvanted versus unadj

121 ptide-MHC-I complex is a better correlate of immunogenicity compared with binding affinity.

122 randomised trial of oral poliovirus vaccine immunogenicity (CTRI/2014/05/004588).

123 Immunogenicity data among children given their first mea

124 ommittee for Immunization Practices based on immunogenicity data, and no studies in the United States

125 This study provides further safety and immunogenicity data.

126 was undertaken to address the impact of the immunogenicity derived from the Fc and variable domains.

127 clarified mechanisms underlying PF4/heparin immunogenicity, disease susceptibility, and clinical man

128 With improved antigenicity, stability, and immunogenicity, DS-SOSIP.4mut-stabilized trimers may hav

129 in the recipient is associated with impaired immunogenicity, elevated viral load and accelerated CD4(

130 T cells, here we compared the HIV-1-specific immunogenicity elicited in nonhuman primates immunized w

131 ants receiving all study injections, primary immunogenicity endpoints were anti-P2-VP8-P[8] IgA and I

132 mmunogen, suggesting that the mAb had formed immunogenicity-enhancing immune complexes (ICs) with nuc

133 We report the first-in-human safety and immunogenicity evaluation of PENNVAX-G DNA/modified vacc

134 study is continuing for long-term safety and immunogenicity follow-up.

135 nce of latent bacilli with IPT modulates BCG immunogenicity following revaccination.

136 They trigger immunogenicity from antigenic subunits that would otherw

137 r the generation of mature DCs with enhanced immunogenicity from pluripotent stem cells.

138 with appropriate attenuation yet sufficient immunogenicity has proven challenging.

139 but the complex mechanisms regulating tumor immunogenicity have not been elucidated.

140 nation on Y2 relative vaccine efficacy (VE), immunogenicity (hemagglutination inhibition [HAI] titers

141 le to a virulent parental strain in terms of immunogenicity, HSV-1 0DeltaNLS does not induce signific

142 heir binding, kinetic complex stability, and immunogenicity in A2-transgenic mice and on peripheral b

143 minants of the balance between tolerance and immunogenicity in AAV vector-mediated gene transfer are

144 ing this a new possible indicator of vaccine immunogenicity in children.

145 elationship between antigen localization and immunogenicity in infected C57BL/6 mice was systematical

146 tor that has already demonstrated safety and immunogenicity in multiple HIV-1 phase I clinical studie

147 nd our rVSV-ZIKV constructs showed efficient immunogenicity in murine models.

148 o study this phenomenon and to determine the immunogenicity in new HIV-1 Env trimer vaccine designs.

149 mulsion adjuvant (MF-59) may lead to greater immunogenicity in organ transplant recipients.

150 ag-Pol-Nef antigens (NYVAC-C) showed limited immunogenicity in phase I clinical trials.

151 We tested these V1V2-scaffold proteins for immunogenicity in rabbits and assessed the responses by

152 T cells and establishes a program of reduced immunogenicity in recently infected B cells, allowing th

153 We here assess DS-Cav1 F immunogenicity in seropositive cattle pre-exposed to bov

154 Immunogenicity in stage 2 was assessed at months 6, 12,

155 to vector virions, significantly increased F immunogenicity in the bivalent RSV/HPIV3 vaccine.

156 nfluenza vaccine is known to have suboptimal immunogenicity in transplant recipients.

157 roperties of such trimers in vitro and their immunogenicity in various animals; and the immunization

158 to explore the mechanisms of this diminished immunogenicity in vitro.

159 The improved immunogenicity included induction of increased titers of

160 ere we introduce a new concept 'neutralizing immunogenicity index' (NII) to evaluate an epitope's neu

161 Six months after peak immunogenicity, infants maintained higher levels Env-spe

162 k to interpret ELISpot data (BIITE: Bayesian Immunogenicity Inference Tool for ELISpot); specifically

163 ved L-asparaginases are of bacterial origin, immunogenicity is a challenge, which would be mitigated

164 valuating and mitigating the risk of product immunogenicity is critical for the development these pro

165 Immunogenicity is furthermore decreased, allowing longer

166 r implication in plant virus recognition and immunogenicity is not well defined.

167 ity and may contribute to the diminished RVV immunogenicity observed in developing countries.

168 The immunogenicities of new peptides were assessed in outbre

169 The effect of age at first dose on the immunogenicity of a 2-dose pediatric schedule of measles

170 We aimed to assess the safety and immunogenicity of a bioconjugate vaccine containing the

171 This study assessed the safety and immunogenicity of a CRM197-conjugated trivalent GBS vacc

172 ssed secreted gp140 (MVAgp140) could improve immunogenicity of a DNA prime-MVA boost vaccine.

173 The safety and immunogenicity of a live attenuated, recombinant tetrava

174 we demonstrate the feasibility, safety, and immunogenicity of a vaccine that targets up to 20 predic

175 could potentially be utilized to reduce the immunogenicity of a wide range of nanomaterials.

176 n this study, we investigated the safety and immunogenicity of an avian H5N2 live attenuated influenz

177 7-specific T cell epitope in determining the immunogenicity of an influenza vaccine.

178 accine development is the enhancement of the immunogenicity of antigens while maintaining safety.

179 e that autophagy and polyploidy increase the immunogenicity of cancer cells mostly by affecting their

180 lopment of novel drugs that may increase the immunogenicity of cancer cells succumbing to treatment.

181 tibodies and has the potential to assess the immunogenicity of candidate antigens, which could be exp

182 to investigate the safety, tolerability, and immunogenicity of ChAd3-EBO-Z in Malian and US adults, a

183 The main objectives were safety and immunogenicity of ChAd3-EBO-Z.

184 ants with CMA may reflect inherited systemic immunogenicity of CM proteins in these families, althoug

185 ermine the relative purity, composition, and immunogenicity of DB particles.

186 -related tumors and that p16 may enhance the immunogenicity of DC, through cyclin-dependent pathways,

187 In this study, the immunogenicity of Delta123 was examined.

188 improved antigenicity, thermostability, and immunogenicity of DS-SOSIP.4mut suggest utility as an im

189 allergen, Ara h2, we directly determined the immunogenicity of each epitope, alone and in combination

190 tential allergy epitopes for determining the immunogenicity of each IgE binding epitope.

191 With respect to the immunogenicity of ferroptosis, Fer-1 prevented the upreg

192 The immunogenicity of fractional (one-fifth, 0.1 mL) intrade

193 he links between the T-cell epitopes and low immunogenicity of H7 HA remains unknown due to the lack

194 umanized mouse model to recapitulate the low immunogenicity of H7 HA.

195 Strategies are needed to improve the immunogenicity of HIV-1 envelope (Env) antigens (Ag) for

196 (IFN-alpha/beta) signaling on virulence and immunogenicity of HSV-1 0DeltaNLS and uncover a probable

197 ver, a greater understanding of the inherent immunogenicity of human iPSC and their cellular derivati

198 The immunogenicity of Id-3F7.A10 raises the possibility that

199 eories will further our understanding of the immunogenicity of individual HLA eplets.It has become ap

200 The immunogenicity of infliximab and adalimumab is a major c

201 Multiple studies have assessed immunogenicity of intradermal fIPV compared with the ful

202 a dose-matched study in rats, comparing the immunogenicity of IPV2 delivered by intramuscular inject

203 Little is known about the immunogenicity of live-attenuated Oka/Merck varicella zo

204 hallenges with the production and suboptimal immunogenicity of malaria vaccine candidates have slowed

205 tens remains challenging due to both the low immunogenicity of many haptens and the cross-reactivity

206 cal virus watch data also indicates a higher immunogenicity of minor-group viruses, consistent with o

207 uate safety, activity, pharmacokinetics, and immunogenicity of moxetumomab pasudotox in children, ado

208 Here, we compare the relative immunogenicity of Nanopatch immunisation versus intramus

209 d, while no protein function correlates with immunogenicity of novel proteins.

210 cholera outbreaks, little is known about the immunogenicity of oral cholera vaccines (OCV) in African

211 The long-term immunogenicity of PCV13 in pneumococcal vaccine-naive ol

212 ide novel genetic markers for predicting the immunogenicity of PEG and efficacy of PEGylated therapeu

213 defines a strategy to rationally improve the immunogenicity of peptides and will have broad applicabi

214 We found that the number and immunogenicity of peptides associated with nonclassical

215 ns provide new mechanistic insights into the immunogenicity of PF4/heparin complexes.

216 For example, PEGylation reduces the immunogenicity of protein cage-based delivery systems an

217 -stimulating factor (GM-CSF) can enhance the immunogenicity of rabies vaccines.

218 nd the effect of the chemokine CXCL13 on the immunogenicity of RABV was investigated.

219 Safety and immunogenicity of RG7787 is now being assessed in a phas

220 The immunogenicity of RIV4 was comparable to that of IIV4; t

221 ever, recent findings have revealed that the immunogenicity of stem cells may have been underestimate

222 Immunogenicity of surrogate Abs may therefore represent

223 phoryl lipid A can significantly improve the immunogenicity of TACAs, thus opening access to potentia

224 on exposure, route of exposure, and overall immunogenicity of the allergen.

225 The results show safety and immunogenicity of the CMVPepVax vaccine.

226 epitope sequence significantly improved the immunogenicity of the H7 HA in the humanized mouse model

227 e of the receptors underlying the remarkable immunogenicity of the mycobacterial cell wall, via recog

228 To assess the immunogenicity of the Nanopatch, we performed a dose-mat

229 We assessed the safety and immunogenicity of the P2-VP8-P[8] subunit rotavirus vacc

230 ffect of the overexpression of CXCL13 on the immunogenicity of the RABV was evaluated in a mouse mode

231 ding of the role of CXCL13 expression in the immunogenicity of the RABV, which may help in designing

232 We report the safety and immunogenicity of the recombinant vesicular stomatitis v

233 ally derived antibodies adversely affect the immunogenicity of the routine schedule, we predict event

234 Immunogenicity of the TLR8 agonist adjuvanted antigen 85

235 The primary objective was safety and immunogenicity of the ZPIV candidate.

236 odies is challenging due to the poor overall immunogenicity of these bacterial targets.

237 Differential immunogenicity of these concentrates has been documented

238 The enhanced immunogenicity of these vectors, mainly from the MV that

239 investigated if Alum-TLR7 is able to improve immunogenicity of this class of vaccines.

240 eria toxin CRM197 improves significantly the immunogenicity of this protein in mice, which illustrate

241 To assess the safety and immunogenicity of three dose levels of the AERAS-402 liv

242 for vaccine delivery that could improve the immunogenicity of vaccines.

243 improvements in cellular immunotherapy, the immunogenicity of virus-specific T cells has not yet bee

244 hildren, rB/HPIV3 was well tolerated but the immunogenicity of wild-type RSV F was unsatisfactory.

245 replicate enhances safety at the expense of immunogenicity, often necessitating multiple doses and b

246 nd that GP1 N-glycan loss does not influence immunogenicity or vaccination success.IMPORTANCE The Wes

247 Secondary immunogenicity outcomes are antibody titres at day 28 an

248 ol, and followed for one year for safety and immunogenicity outcomes.

249 the Philippines) to determine its safety and immunogenicity over 48 months in healthy participants ag

250 the 1 + 1 schedule had significantly greater immunogenicity post-booster than those given the 2 + 1 s

251 We describe for the first time the immunogenicity profile in animal models of UL40, a novel

252 Our data confirm the acceptable safety and immunogenicity profile of the 2 x 107 PFU dose in adults

253 9vHPV vaccine and qHPV vaccine had a similar immunogenicity profile with respect to HPV 6, 11, 16, an

254 It also presents immunogenicity properties, and is considered a target fo

255 immunized into BALB/c mouse to determine the immunogenicity, protection and synergetic effect between

256 in Betaseron could contribute to the higher immunogenicity rates seen in clinics.

257 Cellular immunogenicity, reactogenicity, and safety appeared to b

258 HZ/su cellular immunogenicity, reactogenicity, and safety were also ass

259 v 1-flagellin fusion proteins show enhanced immunogenicity, reduced allergenicity, and intrinsic adj

260 Higher immunogenicity resulting in better antibody capture but

261 Combined safety and immunogenicity results of MVA in allogeneic hematopoieti

262 The immunogenicity results support selection of the 2 x 10(7

263 Appreciating these differences may inform immunogenicity risk assessments.

264 ssues such as biomechanical incompatibility, immunogenicity risks and the hazards of thrombus formati

265 We assessed vaccine immunogenicity, safety, and three primary outcomes: the

266 s in 18-49 year old adults showed comparable immunogenicity, safety, and tolerability for both vaccin

267 osis is the primary cause of FA-AKI and that immunogenicity secondary to ferroptosis may further wors

268 immunisation, and potentially offer improved immunogenicity, simplicity, cost-effectiveness, acceptab

269 Moreover, this is the first immunogenicity study using epitope-targeting, rationally

270 ibodies against DENV-1-4 in the per-protocol immunogenicity subset at 1 month, 3 months, and 6 months

271 occurred; 15 (3%) of 562 participants in the immunogenicity subset reported vaccine-related unsolicit

272 nd solicited and unsolicited adverse events (immunogenicity subset).

273 2 participants were randomly assigned to the immunogenicity subset, of which 503 were included in the

274 TDV or placebo at 0, 6, and 12 months in the immunogenicity subsets of 2 phase 3 trials (clinical tri

275 At peak immunogenicity, the magnitudes of the gp120- and V1V2-sp

276 s/MAPK pathway inhibition can increase tumor immunogenicity, the negative impact on T-cell activity i

277 ng superior thermostable characteristics and immunogenicity, this study progresses the translation of

278 A system, there was no significant change in immunogenicity to either vaccine.

279 fications confer increased stability and low immunogenicity to in vitro transcribed mRNAs, thereby fa

280 neoantigen quantity model ascribing greater immunogenicity to increasing neoantigen number alone did

281 gen quality fitness model conferring greater immunogenicity to neoantigens with differential presenta

282 ment of novel adjuvants is needed to enhance immunogenicity to provide better protection from seasona

283 Immunogenicity trials of licensed or unlicensed vaccines

284 ways that can be targeted to activate cancer immunogenicity via TEs in AML and MDS.

285 Immunogenicity, viraemia, and shedding post-vaccination

286 at population, and the primary evaluation of immunogenicity was a non-inferiority analysis.

287 Immunogenicity was assessed in serum bactericidal assays

288 Immunogenicity was determined in serum bactericidal anti

289 SIP.664-E64K.M1M7, was tested in rabbits, V3 immunogenicity was eliminated while the autologous NAb r

290 ine or placebo), and the primary outcome for immunogenicity was IgG ELISA antibody titres at day 28 i

291 In an effort to decrease immunogenicity, we tested different toxic moieties, incl

292 vents version 4.03, and pharmacodynamics and immunogenicity were also evaluated.

293 d secondary end points related to safety and immunogenicity were assessed throughout the first 8 week

294 Safety and immunogenicity were assessed.

295 Safety and immunogenicity were evaluated over 12 weeks after immuni

296 o be efficiently biodegraded and possess low immunogenicity when implanted subcutaneously in rats.

297 lation by decreasing its permselectivity and immunogenicity while allowing physiological islet functi

298 displaying allergens on VLPs increases their immunogenicity while reducing their potential to cause a

299 ckpoint blockade depends upon inherent tumor immunogenicity, with variation in infiltrating T cells c

300 f peptides in plant pollens and their T-cell immunogenicity within P pratense, as well as their abili